AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Vanguard Total Stock Mkt Idx Inv

Vanguard Institutional 500 Index Trust

American Funds Capital Income Bldr A

Schwab US Dividend Equity ETF™

The Health Care Select Sector SPDR® ETF

Vanguard Institutional Index I

Vanguard Dividend Appreciation ETF

State St S&P 500® Indx SL Cl III

Capital Group Investment Co of Amer Comp

American Funds Invmt Co of Amer A

Vanguard High Dividend Yield ETF

American Funds Income Fund of Amer A

SPDR® S&P 500® ETF Trust

Fidelity 500 Index

iShares Core S&P 500 ETF

Capital Group American Mutual Comp

American Funds American Mutual A

Capital Group Wash Mutual Invtrs Comp

American Funds Washington Mutual A

Vanguard Value Index Inv

Vanguard Group Inc

BlackRock Inc

Bank of America Corp

Northern Trust Corp

Bank of New York Mellon Corp

Capital World Investors

Legal & General Group PLC

Franklin Resources Inc

Ameriprise Financial Inc

FMR Inc

UBS Group AG

Goldman Sachs Group Inc

State Street Corp

JPMorgan Chase & Co

Morgan Stanley - Brokerage Accounts

Capital Research & Mgmt Co - Division 3

Geode Capital Management, LLC

Capital Research Global Investors

Charles Schwab Investment Management Inc

NORGES BANK

AbbVie Inc

Mr. Richard A. Gonzalez

Executive Chairman

Mr. Robert A. Michael

CEO & Director

Mr. Scott T. Reents

Executive VP & CFO

Dr. Azita  Saleki-Gerhardt Ph.D.

Executive VP & COO

Mr. Jeffrey Ryan Stewart

Executive VP & Chief Commercial Officer

Dr. Roopal  Thakkar M.D.

Executive VP of Research and Development & Chief Scientific Officer

Ms. Elizabeth  Shea

Senior Vice President of Investor Relations

Mr. Perry C. Siatis

Executive VP, General Counsel & Secretary

Mr. Sanjay  Narayan

Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal

Mr. Timothy J. Richmond

Executive VP & Chief Human Resources Officer

ABBV's next earnings is on January 31, 2025 (Before Market Open)

ABBV's latest dividend is 1.55 USD on July 15, 2024

AbbVie Inc (ABBV) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

AbbVie Inc (ABBV) Earnings Report Date and History | NYSE

ABBV's next earnings is on January 31, 2025 (Before Market Open)

When is the earnings report for ABBV?

ABBV Earnings History

ABBV's latest dividend is 1.55 USD on July 15, 2024

ABBV Stock Discussion Forum and Message Board

News for NYSE: ABBV